Juniper Pharma Services has expanded its Xcelodose powder micro-dosing system as part of its GMP capabilities for early stage capsule filling. Xcelodose enables Juniper to fill API directly into capsules in an automated manner to primarily support first-in-human studies, reduce formulation requirements and minimize drug substance waste.  Claire Madden-Smith, senior vice president at Juniper Pharma Services, said, “We have focused on having a broad range of development capabilities to enable o...